Dr Hayne talks to ecancer at ASCO 2025 about the phase 3 randomized trial ANZUP 1301 which evaluated whether combining mitomycin with BCG (BCG+MM) as intravesical therapy improves outcomes for patients with high-risk, non–muscle-invasive bladder cancer (NMIBC), compared to standard BCG alone. 

Although BCG+MM involved fewer BCG doses and more total instillations, it had comparable safety and fewer treatment discontinuations than BCG alone. Additionally, a higher proportion of patients completed ≥75% of planned treatments in the BCG+MM group.

Dr Hayne notes that BCG+MM is an effective and safe alternative to BCG alone, with reduced BCG use and better treatment adherence.